Monday 14 October 2019 ,
Monday 14 October 2019 ,
Latest News
  • Mia Seppo summoned over Abrar murder statement
  • Writ seeks ban on student politics at universities
  • Want to get Bangladesh ready to face any calamity: PM
  • 8 ABT men indicted in Dipan murder case
  • ‘Please free my son, forgive his mistakes’: Samrat’s mother to PM
  • Abrar killers won’t be spared: Law minister
16 September, 2019 00:00 00 AM

Anti-addiction meds can help teen Opioid abusers

HealthDay
Anti-addiction meds can help teen Opioid abusers

The epidemic of opioid addiction and abuse ravaging the United States is also affecting teenagers.

Now, research confirms that anti-addiction medications that help adult abusers can also help teen patients.

"Adolescents with severe opioid use disorder may benefit from a medication as part of a larger comprehensive treatment plan," said study lead author Dr. Deepa Camenga, from the Yale School of Medicine.

Her team noted that while the effectiveness of meds such as methadone, buprenorphine or naltrexone in treating adults with opioid addiction is well-established, the evidence for younger patients has been unclear.

To help remedy that, the Yale researchers analyzed data from 14 studies published between 1973 and 2018. They conclude that teens with opioid addiction can be treated with methadone, buprenorphine (Subutex/Suboxone) or extended-release naltrexone (Vivitrol).

The study was published Sept. 11 in the Journal of Studies on Alcohol and Drugs.

There's a pressing need for such treatments, the researchers noted. "In 2017, 900 adolescents started misusing opioid pain relievers each day," they wrote.

So parents who discover that their child is abusing opioids "should try to consult with an addiction psychiatry or medicine specialist to see if there are additional treatments that may benefit their child," Camenga said in a journal news release.

Also, the dangers of untreated opioid addiction "far outweigh the risks" of treatment with methadone, buprenorphine or naltrexone, the study found.

Too many young addicts are going without treatment, however. According to the study team, only about 2%-5% of teens opioid addiction receive treatment with one of the medications listed in the study, compared with 12%-26% of adults.

"There is a great need to improve adolescents' access to medications for the treatment of [opioid addiction] and to increase workforce capacity to care for these adolescents," the authors concluded.

In general, treatment with methadone, buprenorphine or extended-release naltrexone boosted the number of teens who remained in treatment, decreased their opioid use, and led to greater opioid abstinence, according to the study.

Two experts who weren't involved in the study agreed that teens could benefit.

"This health care condition is one that affects all ages, and understanding that options are available to help treat it is vital," said addiction specialist Dr. Sandeep Kapoor, from Northwell Health in New Hyde Park, N.Y. Doctors need to "open up our mindsets and appreciate that even adolescents -- and younger -- should be considered when speaking of addiction treatment.

"As the researchers comment, the risks of untreated opioid use disorder outweigh the risk profiles of the medications available," Kapoor said. "This is the stark reality, and if medication can serve a role in the overall care plan, this should discussed and explored."

Dr. Yili Huang directs the pain management center at Phelps Hospital in Sleepy Hollow, N.Y. He stressed that teenagers with opioid abuse issues should only receive treatments from well-trained professionals.

For example, Huang said, "although an effective opioid addiction treatment, methadone can be a dangerous medication. Methadone should be administered by very experienced providers because there is very much variability on how long and how much remains in the body." In many cases, buprenorphine might be a safer option, he said.

Also, "[medication] availability is often a challenge," Huang said. "Prescribers need to obtain a waiver to prescribe it to patients and many do not treat adolescents."

The Yale study authors agreed that "research is still needed to understand the optimal treatment duration and how to retain adolescents in treatment."

And in an accompanying journal editorial, Rachel Gonzales-Castaneda from the University of California, Los Angeles, and her colleagues stressed that beating opioid addiction can be a real challenge.

"Relapse occurs in more than half of teens with opioid addiction who are treated with standard approaches," they noted, "so alternatives such a treatment with medication may need to be considered."

The editorialists added that there is a lack information on how opioid treatment medications may interact with other mental or physical disorders or their treatments, and that much more research is needed into teen opioid addiction.

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

A joint is formed where two or more bones of skeleton meet one another. The long bones join by their ends and flat bones by their sides. They are mainly…
The basics of arthritis

The basics of arthritis

Arthritis is a broad term that covers a group of over 100 diseases. It has everything to do with your joints -- the places where your bones connect --…
Arthritis treatment 
options

Arthritis treatment options

The treatment options covered in this article relate to osteoarthritis, although many of them may be effective rheumatoid arthritis treatments. Please…
Arthrocentesis and joint injections

Arthrocentesis and joint injections

Arthrocentesis means aspiration of fluid from a joint space which is usually done by placing a needle into a joint space and withdrawing fluid in to a…
Rheumatoid and musculoskeletal diseases (RMDs)

Rheumatoid and musculoskeletal diseases (RMDs)

RMDs are commonly classified into inflammatory and non-inflammatory types: Common non-inflammatory RMDs consist of degenerative spine diseases, osteoarthritis,…
An overview of arthritis mutilans

An overview of arthritis mutilans

LANA BARHUM Arthritis mutilans is a severe form of chronic rheumatoid arthritis or psoriatic arthritis. It is characterized by severe inflammation that…
Paralysed man moves in mind-reading exoskeleton

Paralysed man moves in mind-reading exoskeleton

JAMES GALLAGHER  FA man has been able to move all four of his paralysed limbs with a mind-controlled exoskeleton suit, French researchers report.…
Pain Management of older persons: physiotherapy is the hope

Pain Management of older persons: physiotherapy is the hope

Every year on 1st October, WHO has been playing a significant role in celebrations, and actively promoting public awareness of the “International…
Pain Management of older persons: physiotherapy is the hope

Pain Management of older persons: physiotherapy is the hope

Every year on 1st October, WHO has been playing a significant role in celebrations, and actively promoting public awareness of the “International…
Chinese study reveals underuse of lifesaving drugs after heart attacks

Chinese study reveals underuse of lifesaving drugs after heart attacks

Many heart attack patients in China fail to receive beta-blockers which could prevent another event and save their life. The research is presented at…
Humans may possess ability to regrow cartilage

Humans may possess ability to regrow cartilage

Humans may lack the salamander skill of regrowing a limb, but a new study suggests they do have some capacity to restore cartilage in their joints. The…
Prescribed Zantac heartburn medicine recall in UK

Prescribed Zantac heartburn medicine recall in UK

UK doctors are being told to stop prescribing four types of a heartburn medication called Zantac or ranitidine as a "precautionary measure".…
FDA approves Ibsrela (tenapanor) for the treatment of Irritable Bowel Syndrome with constipation

FDA approves Ibsrela (tenapanor) for the treatment of Irritable Bowel Syndrome with constipation

Ardelyx, Inc. recently announced that the U.S. Food and Drug Administration has approved Ibsrela (tenapanor), a 50 mg, twice daily oral pill for the treatment…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting